Lv21
110 积分 2024-07-11 加入
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
1个月前
已完结
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
2个月前
已完结
Targeting the incretin system in obesity and type 2 diabetes mellitus
2个月前
已完结
Quantum instanton evaluations of surface diffusion, interior migration, and surface-subsurface transport for H/Ni
3个月前
已完结
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
3个月前
已完结
Semaglutide: First Global Approval
3个月前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
3个月前
已完结
Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism
3个月前
已关闭
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
3个月前
已完结
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
3个月前
已完结
皖公网安备34019202002308
